These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30972901)

  • 41. Multigene Combined Detection by RT-qPCR Using Cytological Specimens.
    Ma Y; Zhao J; Du Y; Wang R; Ji X; Wu J; Guo X; Liu Y; Zhang Y
    Acta Cytol; 2021; 65(5):393-402. PubMed ID: 34343999
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.
    Amemiya K; Hirotsu Y; Nagakubo Y; Mochizuki H; Higuchi R; Tsutsui T; Kakizaki Y; Miyashita Y; Oyama T; Omata M
    Cancer Cytopathol; 2021 Sep; 129(9):729-738. PubMed ID: 33872472
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recurrence of lung adenocarcinoma after an interval of 15 years revealed by demonstration of the same type of EML4-ALK fusion gene.
    Tsukamoto Y; Kanamori K; Watanabe T; Mikami K; Ieki R; Nakano T; Kajimoto K; Hirota S
    Pathol Res Pract; 2014 Dec; 210(12):1112-6. PubMed ID: 25238939
    [TBL] [Abstract][Full Text] [Related]  

  • 44. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non-Small-Cell Lung Cancer from Chile, Brazil, and Peru.
    Sepúlveda-Hermosilla G; Freire M; Blanco A; Cáceres J; Lizana R; Ramos L; Assar Cuevas R; Ampuero D; Aren O; Chernilo S; Spencer ML; Bernal G; Flores J; Rasse G; Sánchez C; Marcelain K; Rivas S; Branco GP; Galli de Amorim M; Nunes DN; Dias-Neto E; Freitas HC; Fernández C; ; Pérez P; Armisén R
    J Mol Diagn; 2021 Sep; 23(9):1127-1137. PubMed ID: 34186175
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer.
    Ji JH; Oh YL; Hong M; Yun JW; Lee HW; Kim D; Ji Y; Kim DH; Park WY; Shin HT; Kim KM; Ahn MJ; Park K; Sun JM
    PLoS Genet; 2015 Aug; 11(8):e1005467. PubMed ID: 26295973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.
    Chu YH; Barbee J; Yang SR; Chang JC; Liang P; Mullaney K; Chan R; Salazar P; Benayed R; Offin M; Drilon A; Ladanyi M; Nafa K; Arcila ME
    J Mol Diagn; 2022 Jun; 24(6):642-654. PubMed ID: 35430374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Detection of ALK gene translocation by fluorescence in situ hybridization in paraffin-embedded anaplastic large cell lymphoma tissue and its significance].
    Li HY; Li GD; He XJ; Liu WP; Zhang J; Yang WX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct; 21(5):470-3. PubMed ID: 15476173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
    Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
    J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
    Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
    Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anaplastic Lymphoma Kinase Immunocytochemistry on Cell-Transferred Cytologic Smears of Lung Adenocarcinoma.
    Zhang C; Randolph ML; Jones KJ; Cramer HM; Cheng L; Wu HH
    Acta Cytol; 2015; 59(2):213-8. PubMed ID: 25967762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
    Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
    Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [ALK protein expression and gene fusion in bronchoscopic specimens of lung adenocarcinoma].
    Liang X; Wang M; Zhang J; Luo Y; Zhang S; Wu S; Liu Y; Zeng X
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):501-4. PubMed ID: 25327654
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Usefulness of an RNA extraction-free test for the multiplexed detection of
    Damiola F; Alberti L; Mansuet-Lupo A; Damotte D; Hofman V; Tixier L; Penault-Llorca F; Rouquette I; Vignaud JM; Cazes A; Forest F; Begueret H; Gibault L; Badoual C; Cayre A; Taranchon-Clermont E; Duc A; Mc Leer A; Lantuejoul S
    Expert Rev Mol Diagn; 2023; 23(12):1283-1291. PubMed ID: 37906110
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
    Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
    J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
    Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
    Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.